New Delhi: The Supreme Court will hear a PIL on Tuesday seeking a ban on Ranbaxy drugs. The petitioner cited the pharma giant's case in the US - where Ranbaxy USA admitted to selling substandard and adulterated drugs.
The pharma giant was asked to pay a fine of 500 million dollars. Ranbaxy has been facing the heat off late - with a few hospitals banning its drugs.
The PIL has also sought sealing of all Ranbaxy's manufacturing units in India, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh. In his petition, the advocate has contended that making and selling adulterated drugs is a heinous crime and "amounts to committing murder" and a person who knowingly does it is liable to be prosecuted under the Indian Penal Code.
It also sought action against Indian drug regulator, Central Drug Standards Control Organisation (CDSCO), for permitting Ranbaxy to sell drugs in India, especially in the wake of the results of the USFDA probe against the company.
With Additional Inputs from PTI